IBR2 is a recognized Rad51 inhibitor to impair Rad51 multimerization and promote proteasome-mediated degradation of Rad51 protein to therefore reduce HRR function, which ultimately enhances apoptosis and impairs tumor growth of chronic myeloid leukemia (60). This evidence concerns the gene RAD51 and neoplasm.